A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...

In early November 2025, Akeso announced a series of major developments in its oncology portfolio, including statistically significant Phase III survival results for ivonescimab in EGFR-mutated lung ...

If mass vaccine deaths are imminent, it is not evident in the global life expectancy trends. Since the rollout of billions of mRNA shots beginning in 2021, global life expectancy has risen from 70.9 ...

Among mRNA tech, vaccines have been the primary target of the federal government's ire, despite experts' warnings that ...

When University of Virginia neuroscientist Harald Sontheimer shared this year’s International Prize for Translational ...

Millions, perhaps even billions of us who got ourselves vaccinated against COVID-19 should be dead by now, or if not yet, very soon. For years, prominent wellness influencers and other internet ...

The SPDR S&P 500 ETF Trust ($SPY) rallied 1.54% on Monday, lifted by optimism over a possible end to the U.S. government ...

Get the latest stock market update and key takeaways in healthcare, including Pfizer, Amgen, Novo Nordisk results, and obesity drug bidding wars.

The democratization of investing started with discount brokers slashing commissions and advanced through no-transaction-fee trading on apps like Robinhood (NASDAQ:HOOD) and Fidelity. Now, it no longer ...

A cutting-edge RNA research facility promised to New South Wales more than four years ago will open its doors by next summer, ...

The space and telecom industries can look increasingly intertwined as satellite roaming—today for messages, tomorrow for data ...